| 主权项 |
1. A method of treating a cell proliferation disorder in a subject in need thereof, comprising topically administering to a skin area of the subject a topical composition comprising an effective amount of at least one alpha adrenergic receptor agonist and a pharmaceutically acceptable carrier, wherein the skin area has, or is prone to have, the cell proliferation disorder; the alpha adrenergic receptor agonist is selected from the group consisting of (8-Bromo-quinoxalin-6-yl)-(4,5-dihydro-1H- imidazol-2-yl)-amine, (8-Bromo-quinoxalin-5-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine, (5-Bromo-3-methyl-quinoxalin-6-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine, (5-Bromo-2-methoxy-quinoxalin-6-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine, (4,5-dihydro-1H-imidazol-2-yl)-(8-methyl-quinoxalin-6-yl)-amine, (4,5-dihydro-1H-imidazol-2-yl)-quinoxalin-5-yl-amine, naphazoline, tetrahydrozoline, epinephrine, norepinephrine, phenylephrine, methoxamine, mephentermine, metaraminol, and midodrine; and the cell proliferation disorder is associated with one or more conditions selected from the group consisting of sun exposure, hormonal imbalance, a deficiency in vitamin and/or antioxidant, epidermal hyperplasia, keratinocyte proliferation, EGFR-dependent cell division, hand and foot syndrome, cutaneous T cell lymphoma, and combinations thereof. |
